Core Viewpoint - Rosen Law Firm is reminding purchasers of Revance Therapeutics, Inc. securities about the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for affected investors [1][2]. Group 1: Class Action Details - The class action pertains to securities purchased between February 29, 2024, and December 6, 2024, with a lead plaintiff deadline set for March 4, 2025 [1]. - Investors can join the class action without incurring out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]. Group 3: Case Allegations - The lawsuit alleges that Revance made false and misleading statements and failed to disclose material breaches of agreements, which increased litigation risks and potential harm [4]. - Specific claims include breaches of the Distribution Agreement with Teoxane SA and issues related to a contract with an unreliable partner, leading to misleading public statements [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from February 29, 2024, to December 6, 2024 [1]. - Allegations include that Revance was in material breach of the Distribution Agreement with Teoxane, which granted exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach allegedly increased the risk of litigation and monetary and reputational harm to the company [1]. - The allegations suggest that the company's public statements were materially false and misleading during the class period [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by March 4, 2025, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2]. - The breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2]. - The lawsuit also suggests that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches of agreements during a specified class period [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from February 29, 2024, to December 6, 2024 [1]. - Allegations include that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach allegedly increased the risk of litigation and monetary and reputational harm to the company [1]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action and can do so without any cost or obligation [2]. - The deadline for shareholders to seek lead plaintiff status is March 4, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].

Core Viewpoint - A class action securities lawsuit has been filed against Revance Therapeutics, Inc. for alleged securities fraud affecting investors between February 29, 2024, and December 6, 2024 [1][2] Group 1: Lawsuit Details - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2] - The breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2] - The lawsuit also suggests that these issues raised the likelihood of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A federal securities class action has been filed against Revance Therapeutics, Inc. for alleged misleading statements and material breaches related to its distribution agreement and merger agreement, with a deadline for investors to seek lead plaintiff status by March 4, 2025 [1][6]. Company Overview - Revance Therapeutics entered into a distribution agreement with Teoxane SA in January 2020, granting exclusive rights to market and distribute Teoxane's dermal fillers in exchange for 2.5 million shares of Revance common stock [3]. - In August 2024, Revance announced a merger agreement with Crown Laboratories, with Crown planning to acquire Revance's shares for $6.66 each, totaling an enterprise value of $924 million [3]. Key Events - On September 23, 2024, Revance disclosed a notice of alleged material breaches of the distribution agreement, leading to a delay in Crown's tender offer and a subsequent decline in Revance's share price by 7.66% [4]. - On December 9, 2024, Revance announced an amendment to the merger agreement, reducing the tender offer price to $3.10 per share, over 50% lower than the initial offer, causing a further decline in share price by approximately 20.68% [5]. Allegations - The complaint alleges that Revance made false or misleading statements and failed to disclose material breaches of the distribution agreement, which increased the risk of litigation and affected the tender offer [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Revance Therapeutics, Inc. regarding a class action lawsuit due to alleged misleading statements and material breaches related to a Distribution Agreement with Teoxane [1]. Group 1: Allegations - The complaint alleges that Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [1]. - The breach subjected the company to increased risks of litigation, monetary, and reputational harm [1]. - The allegations suggest that these issues increased the risk of delays or amendments to a tender offer, rendering the company's public statements materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 29, 2024, to December 6, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 4, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflate stock prices [3].

Core Viewpoint - Revance Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 29, 2024, and December 6, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to market and distribute Teoxane's dermal fillers [2] - This breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2] - The situation heightened the risk of delays or amendments to a tender offer, leading to materially false and misleading public statements by the company [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - Revance Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 29, 2024, and December 6, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted it exclusive rights to market and distribute Teoxane's dermal fillers [2] - This breach allegedly increased the risk of litigation and caused monetary and reputational harm to the company [2] - The situation heightened the risk of delays or amendments to a tender offer, leading to materially false and misleading public statements by the company [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3] - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - Revance Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 29, 2024, and December 6, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [2] - This breach allegedly increased the risk of litigation and resulted in potential monetary and reputational harm to the company [2] - The situation heightened the risk that a tender offer would be delayed or amended, leading to materially false and misleading public statements from the company [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]